[Asia Economy Reporter Lee Gwan-joo] Peptron announced on the 27th that its GLP-1 class Parkinson's disease treatment 'PT320' has received 'compassionate use approval' for clinical trial drugs from the Ministry of Food and Drug Safety.
The compassionate use approval system is a system in which the Ministry of Food and Drug Safety permits the use of clinical trial drugs for treatment purposes only before obtaining marketing authorization, to provide treatment opportunities to patients with severe diseases that threaten life or have no alternative treatment options. This system is operated in various countries including the United States and Europe, but only for drugs approved for clinical trials.
A Peptron official stated, "PT320 has the highest blood-brain barrier (BBB) permeability among known GLP-1 class drugs to date and relatively low weight loss rate, making it a suitable treatment for degenerative brain diseases such as Parkinson's disease and Alzheimer's disease. Through this compassionate use approval, we will strive to provide treatment opportunities to patients until the new drug is supplied domestically."
Peptron is currently conducting a domestic Phase 2 clinical trial of PT320 and plans to announce the clinical results within this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
